Press Release: Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates
Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates
-- Total second quarter revenue of $31.5 million increased 62% year-over-year on continued recovery and expansion from impact of COVID-19 pandemic -- Second quarter clinical laboratory revenue of $24.0 million increased 92% on significant volume and pricing growth due to improved product mix -- Consolidated quarterly gross margin of 50% improved 2000 basis points year-over-year -- Achieved adjusted EBITDA at $4.3 million for the quarter with increases in sequential and YOY profitability -- EPS of $0.05 for the quarter vs. EPS loss of ($0.16) in Q2 2020 -- Dr. Elazar Rabbani, Founder and CEO, to step down as CEO and transition to a scientific role with the Company once a qualified successor is identified and hired by the Board -- Executive search firm Korn Ferry engaged to identify CEO candidates -- Gary M. Huff, former LabCorp Diagnostics CEO, named Strategic Consultant to Board -- Enzo retains Cain Brothers to help identify, evaluate, and execute strategic initiatives
Conference call and live webcast scheduled for today,
Monday, March 15, 2021 at 4:30 pm (ET)
NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc (NYSE: ENZ), a leading biosciences and diagnostics company, today reported financial results for the second quarter ended January 31, 2021 and provided a business update on recent corporate and operational developments.
"The Company's strong financial performance in the second quarter is another reflection of the strength of our new business model for integrated diagnostic product and services. The high gross margins achieved this quarter further validate the strength of Enzo's strategy," said Elazar Rabbani, Ph.D., Enzo's Chairman and CEO. "These results are especially indicative of the advancements we have made in development of proprietary products, notably our versatile GENFLEX(TM) molecular diagnostic platform, as well as our integrated end-to-end business strategy that ranges from research through final diagnostic products and services."
Enzo's financial improvement from an operating loss of $16.2 million in 1H 2020 to an operating profit of $2.2 million in 1H 2021, an $18.4 million improvement, supported by management's strategic shift to addressing the COVID-19 pandemic on its proprietary GENFLEX(TM) platform as well as cost efficiencies identified and executed by the Company. These operational measures were achieved despite staff limitations, supply chain interruptions, and other unprecedented circumstances caused by the pandemic.
"Our open system approach allows for the highest levels of flexibility and adaptability in the post COVID-19 environment," said Barry Weiner, Enzo's President. "Our GENFLEX(TM) platform enables laboratories to use third-party or their own reagents on this open platform with ease and flexibility. Through this platform, we can provide substantially lower costs for molecular testing and address reimbursement pressure in one of the fastest growing segments of the clinical testing market."
"We remain committed to our growth strategy and expect that the higher margins achieved by the vertically integrated model of COVID-19 testing can be extended to a range of other molecular tests as well as key platforms such as immunohistochemistry (IHC) and cytology, both of which can face challenges as a result of widespread use of closed system platforms," continued Mr. Weiner. "We are currently validating test menus and panel extensions to drive utility in the high-volume molecular testing space through deployment of Enzo's internal sales and marketing operations as well as with industry partners."
After years of dedicated service, Dr. Elazar Rabbani, Founder and CEO, will remain a Director of the Company and will step down as CEO and transition to a scientific role with the Company once a qualified successor is identified and hired by the Board. To fully capitalize on the potential of Enzo's business model, the Company and the Board of Directors have retained the global search firm Korn Ferry to conduct the CEO search.
In addition, the Company also announced that Gary Huff, the former CEO of LabCorp Diagnostics, will serve as a strategic consultant to the Board. Mr. Huff is an industry veteran who held multiple positions of increasing responsibility at LabCorp and demonstrated a strong history of leadership and business acumen. He was formerly CEO of Baylor Genetics Laboratories where he provided leadership and guidance on the continuous development of their product pipeline.
To assist with strategic initiatives, the Company has also retained Cain Brothers, a healthcare investment banking firm, to help identify, evaluate and execute strategic and commercial opportunities.
Second Quarter 2021 and Recent Business Highlights
-- Announced results of an analysis showing that tests processed on the Company's proprietary GENFLEX(TM) molecular diagnostic platform are successfully able to detect the presence of currently known variants of COVID-19. While the Company's PCR testing does not distinguish between different variants, positive samples can be further analyzed for variant identification. Rapid antigen tests currently available in the marketplace do not have this capability. -- Received an expansion of its Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) authorizing the use of pooled samples containing up to five individual swab specimens with the Company's AMPIPROBE(R) SARS-Cov-2 Test System utilizing tests on three different platforms including Enzo's proprietary GENFLEX(TM) automated high-throughput platform. -- Received a U.S. Patent for polyclonal antibodies against osteoporosis drug target sclerostin. This patent is a member of a broader U.S. and international patent family that also includes issued patents and pending patent applications for therapies including monoclonal antibodies and small synthetic peptides used to inhibit sclerostin in the treatment of bone disorders such as osteoporosis.
Second Quarter 2021 Financial Results
-- Total second quarter revenue was $31.5 million, an increase of 62% from $19.4 million in the second quarter last year. The gains reflected continued increased activity, particularly related to COVID-19. Consolidated gross margin was 50.3%, a 2,030 basis points improvement, vs 30.0% in the year ago period. -- Enzo Clinical Lab revenues totaled $24.0 million, an increase of 92% from $12.5 million in the second quarter last year. This performance was primarily driven by services accession count exceeding 330,000 in the quarter compared to approximately 200,000 a year ago, an increase of nearly 65% year-over-year. Clinical services margin advanced to 51.2%, from 18.1% in the year-ago comparable period and 38.8% in the preceding quarter, largely due to testing mix and ongoing cost-saving initiatives. -- Enzo Life Sciences revenue was $7.5 million, an increase of 9% compared with $6.9 million in the year ago period. The average product order value increased 18% during the period, due mainly to servicing higher value markets. Gross margin was 47.4%, lower than the 51.5% gross margin in the year ago period, but was flat when accounting for intercompany sales. -- Research and development expenses declined 24% to $0.8 million, or 2.6% of total revenues, from $1.1 million, or 5.5% of total revenues, in the year ago period. Selling, general and administrative expenses of $11.0 million rose slightly from $10.7 million in year ago period, although SG&A margin declined by more than 2000 basis points due to better fixed cost leverage as a result of vertical integration and cost efficiency measures. -- GAAP net income totaled $2.3 million, or $0.05 per share, compared with a loss of ($7.7) million, or ($0.16), in the year-ago quarter, an improvement of almost $10 million. Adjusted EBITDA in the quarter totaled $4.3 million, versus an adjusted EBITDA loss of $5.4 million in the second quarter of 2020. The year-over-year increase was driven mainly by improvement in gross margin (from COVID-19 testing and lower reagent and reference lab costs) and lower SG&A expenses from headcount efficiencies, lower intangibles amortization, and reduced travel. -- Cash and cash equivalents totaled $44.5 million as of January 31, 2021, slightly lower than the $47.9 million at the end of fiscal year 2020, due to investments in inventory, higher accounts receivable and capital expenditures, and lower accounts payable. Working capital amounted to $40.0 million, compared to $36.0 million as of July 31, 2020. As of January 31, 2021, the Company had 48.2 million shares outstanding.
(MORE TO FOLLOW) Dow Jones Newswires
March 15, 2021 16:05 ET (20:05 GMT)